Bhinder, Bhavneet, Antczak, Christophe, Shum, David, Radu, Constantin, Mahida, Jeni, Liu-Sullivan, Nancy, Ibanez, Glorymar, Somalinga Raja, Balajee, Calder, Paul and Djaballah, Hakim (2014) Chemical & RNAi Screening at MSKCC: A Collaborative Platform to Discover & Repurpose Drugs to Fight Disease. Combinatorial Chemistry & High Throughput Screening, 17 (4). pp. 298-318. ISSN 1875-5402

Abstract

Memorial Sloan-Kettering Cancer Center (MSKCC) has implemented the creation of a full service state-of-the-art High-throughput Screening Core Facility (HTSCF) equipped with odern robotics and custom-built screening data management resources to rapidly store and uery chemical and RNAi screening data outputs. The mission of the facility is to provide ncology clinicians and researchers alike with access to cost-effective HTS solutions for both hemical and RNAi screening, with an ultimate goal of novel target identification and drug iscovery. HTSCF was established in 2003 to support the institution’s commitment to growth in olecular pharmacology and in the realm of therapeutic agents to fight chronic diseases such as ancer. This endeavor required broad range of expertise in technology development to establish obust and innovative assays, large collections of diverse chemical and RNAi duplexes to probe pecific cellular events, sophisticated compound and data handling capabilities, and a profound nowledge in assay development, hit validation, and characterization. Our goal has been to strive or constant innovation, and we strongly believe in shifting the paradigm from traditional drug iscovery towards translational research now, making allowance for unmet clinical needs in patients. Our efforts towards epurposing FDA-approved drugs fructified when digoxin, identified through primary HTS, was administered in the clinic for treatment of stage Vb retinoblastoma. In summary, the overall aim of our facility is to identify novel chemical probes, to study cellular processes relevant to investigator’s research interest in chemical biology and functional genomics, and to be instrumental in accelerating the process of drug discovery in academia.

Item Type:	Article
Date Deposited:	13 Oct 2015 13:12
Last Modified:	04 Jul 2016 23:45
URI:	https://oak.novartis.com/id/eprint/22436